U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06878365) titled 'A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies' on March 13.
Brief Summary: This study is open to adults with selected type 1 interferonopathies. People can join the study if they have Aicardi-Goutieres syndrome (AGS), Coatomer subunit alpha (COPA) syndrome, Familial chilblain lupus (FCL), or another type 1 interferonopathy with a specific gene mutation.
The purpose of this study is to find out how BI 3000202 is tolerated in people with selected type 1 interferonopathies. Participants take a lower dose of BI 3000202 as tablets for 4 weeks. Afterwards, they take a higher dose of BI 3000202...